Results 21 to 30 of about 23,766 (215)
Vaccines, 2021 The only currently available anti-tuberculosis vaccine, Bacillus Calmette–Guérin (BCG), has been reported to also protect against unrelated diseases, including inflammatory diseases such as allergic asthma. Recombinant BCG strains that produce IL-18 have
Magdalena Kowalewicz-Kulbat +7 more
doaj +1 more source
Protective efficacy of BCG overexpressing an L,D-transpeptidase against M. tuberculosis infection. [PDF]
PLoS ONE, 2010 M. bovis Bacille Calmette-Guérin (BCG), currently the only available vaccine against tuberculosis (TB), fails to adequately protect individuals from active and latent TB infection.
Scott T Nolan, Gyanu Lamichhane
doaj +1 more source
The glycosylated Rv1860 protein of Mycobacterium tuberculosis inhibits dendritic cell mediated TH1 and TH17 polarization of T cells and abrogates protective immunity conferred by BCG. [PDF]
PLoS Pathogens, 2014 We previously reported interferon gamma secretion by human CD4⁺ and CD8⁺ T cells in response to recombinant E. coli-expressed Rv1860 protein of Mycobacterium tuberculosis (MTB) as well as protection of guinea pigs against a challenge with virulent MTB ...
Vijaya Satchidanandam +5 more
doaj +1 more source
mBio, 2022 Mycobacterium tuberculosis infects approximately one-third of the world's population, causing active tuberculosis (TB) in ~10 million people and death in ~1.5 million people annually. A potent vaccine is needed to boost the level of immunity conferred by
Qingmei Jia +3 more
doaj +1 more source
Frontiers in Immunology, 2020 While Baccillus Calmette-Guerin (BCG) is used worldwide, tuberculosis (TB) is still a global concern due to the poor efficacy of BCG. Novel vaccine candidates are therefore urgently required.
Si-Jing Liu +12 more
doaj +1 more source
CFP10: mFcγ2 as a novel tuberculosis vaccine candidate increases immune response in mouse [PDF]
Iranian Journal of Basic Medical Sciences, 2017 Objective(s): Despite treatment with antibiotics and vaccination with BCG, tuberculosis (TB) is still considered as one of the most important public health problems in the world.
Ali Asghar Baghani +10 more
doaj +1 more source
Frontiers in Immunology, 2022 Tuberculosis is one of the deadliest infectious diseases and a huge healthcare burden in many countries. New vaccines, including recombinant BCG-based candidates, are currently under evaluation in clinical trials.
Luana Moraes +9 more
doaj +1 more source
Sleeping Beauty and the Story of the Bacille Calmette-Guérin Vaccine
mBio, 2016 Mycobacterium bovis BCG is the only available vaccine for protection against tuberculosis (TB). While BCG protects children from severe disease, it has little impact on pulmonary disease in adults. A recombinant BCG vaccine BCG ΔureC::hly (strain VPM1002)
Helen A. Fletcher
doaj +1 more source
Tuberculosis vaccine: pipeline approaches and future prospective [PDF]
, 2011 Tuberculosis (TB), despite anti-mycobacterial therapies and vaccine, is a deadly infectious disease with about 12 million incident cases worldwide. Existing Bacillus Calmette-Guérin (BCG) vaccine is unquestionably inexpensive, safe and effective ...
Ankita Singh +2 more
core +2 more sources
Recombinant Mycobacterium bovis BCG as an HIV Vaccine Vector [PDF]
Current HIV Research, 2010 HIV-1 has resulted in a devastating AIDS pandemic. An effective HIV/AIDS vaccine that can be used to either, prevent HIV infection, control infection or prevent progression of the disease to AIDS is needed. In this review we discuss the use of Mycobacterium bovis BCG, the tuberculosis vaccine, as a vaccine vector for an HIV vaccine.
Rosamund, Chapman +4 more
openaire +2 more sources